Provided by Tiger Fintech (Singapore) Pte. Ltd.

BEIGENE

210.000
+4.2002.04%
Volume:6.16M
Turnover:1.29B
Market Cap:323.40B
PE:-57.24
High:213.000
Open:205.600
Low:204.600
Close:205.800
52wk High:213.000
52wk Low:103.100
Shares:1.54B
HK Float Shares:1.43B
Volume Ratio:0.73
T/O Rate:0.43%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-3.669
ROE:-4.98%
ROA:-1.06%
PB:11.01
PE(LYR):-57.24
PS:9.10

Loading ...

Market Chatter: WuXi AppTec Chairman Tops China's A-List for Highest Pay in 2024

MT Newswires Live
·
May 09

BeiGene Is Maintained at Buy by Guggenheim

Dow Jones
·
May 08

RBC Trims Price Target on BeiGene to $311 From $312, Keeps Outperform Rating

MT Newswires Live
·
May 08

BeiGene Turns to Q1 Profit

MT Newswires Live
·
May 08

BeiGene Narrows Q1 Loss as Operating Income Jumps 50%

MT Newswires Live
·
May 08

Chinese Biotech BeiGene Stock Falls Despite Strong Brukinsa Sales And Earnings Beat

Benzinga
·
May 07

BeiGene Swings to Q1 Adjusted Earnings, Revenue Increases; 2025 Revenue Outlook Reiterated

MT Newswires Live
·
May 07

CORRECTION: BeiGene Q1 Adj. EPADS $1.22 Beats $(0.74) Estimate, Sales $1.12B Miss $1.14B Estimate

Benzinga
·
May 07

BRIEF-Beigene Says Pharmacyclics Litigation Is Not Expected To Affect Operation

Reuters
·
Apr 30

BeiGene Price Target Maintained With a $312.00/Share by RBC Capital

Dow Jones
·
Apr 28

BeiGene Is Maintained at Overweight by JP Morgan

Dow Jones
·
Apr 22

BeiGene Price Target Maintained With a $348.00/Share by Guggenheim

Dow Jones
·
Apr 10

Hong Kong Stocks Reverse Early Losses to End Higher; Pharma Stocks Slide

MT Newswires Live
·
Apr 09

Hong Kong Pharma Stocks Decline as Trump Threatens Tariffs on Imported Drugs

MT Newswires Live
·
Apr 09

BeiGene Initiated at Outperform by RBC Capital

Dow Jones
·
Apr 07

RBC Initiates BeiGene at Outperform With $312 Price Target

MT Newswires Live
·
Apr 07

BeiGene to Discontinue Potential Lung Cancer Treatment Study

MT Newswires Live
·
Apr 03

BeiGene Scraps Ociperlimab Lung-Cancer Drug Candidate

Dow Jones
·
Apr 03

BeiGene Says EMA Panel Recommends Approval of Tevimbra for Lung Cancer

MT Newswires Live
·
Mar 31

BeiGene Net Loss Narrows 27% in 2024

MT Newswires Live
·
Mar 28